Discover MammoScreen at RSNA Annual Meeting
Pierre Fillard, Ph.D., Therapixel Founder and CSO, will present at the 105th Scientific Assembly & Annual Meeting of the Radiological Society of North America (RSNA 2019) to be held from December 1-6, at McCormick Place in Chicago.
In this presentation, Pierre Fillard will introduce MammoScreen*, Therapixel’s award-winning AI-based algorithm that enhances mammography screening. Developed in collaboration with radiologists, MammoScreen helps them interpret screening mammograms.
Due to its outstanding performance, in 2017 an early version of MammoScreen won the largest global AI competition ever organized – Digital Mammography DREAM Challenge , leaving 1200 competitors behind. Since then, the algorithm has been further refined, enabling highly reliable breast cancer detection at first reading.
Why it is important
Breast cancer affects one in eight women during their lifetime. The cornerstone of its successful treatment is an early diagnosis. Even though mammography is the most common screening test for breast cancer, it has some limitations. For instance, systematic screening leads to a recall of 10 percent of patients for a complimentary examination. However, only 5 percent of them are actually affected by the disease.
About RSNA Annual Meeting
RSNA Annual Meeting has become one of the most important events in radiology, bringing together leading specialists from all over the world. The attendees will discover the latest technological innovations and explore a range of topics from radiology education to mammography research. This year’s meeting promises to feature an expanded artificial intelligence (AI) presence.
About Therapixel
Therapixel is a leading French software company specialized in artificial intelligence for medical imaging. We aim to take mammography screening to a whole new level by developing MammoScreen, an AI-based algorithm capable of recognizing malignancy in mammograms. MammoScreen will work hand in hand with radiologists to help them make a faster and more accurate diagnosis and reduce unnecessary recalls.
*MammoScreen is currently not available for sale within the United States.